🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

15+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 15 of 15 recruiting trials for “hereditary-angioedema-with-normal-c1inh

Phase 3RecruitingNCT07298447

Donidalorsen Treatment in Children With Hereditary Angioedema

🏥 Ionis Pharmaceuticals, Inc.📍 3 sites📅 Started Jul 2026View details ↗
NARecruitingNCT07251933

A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple Countries

👨‍⚕️ Study Director, Takeda📍 20 sites📅 Started Feb 2026View details ↗
Phase 3Enrolling by InvitationNCT07204938

A Long-Term Study of Navenibart in Participants With Hereditary Angioedema

🏥 Astria Therapeutics, Inc.📍 1 site📅 Started Oct 2025View details ↗
Phase 3RecruitingNCT06960213

STOP-HAE: A Phase 3 Study of ADX-324 in HAE

👨‍⚕️ Lauge Farnaes, MD, ADARx Pharmaceuticals, Inc.📍 14 sites📅 Started Aug 2025View details ↗
NARecruitingNCT07001280

A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)

👨‍⚕️ Global Program Director, CSL Behring📍 9 sites📅 Started Jul 2025View details ↗
Phase 3RecruitingNCT06842823

A Study of Navenibart in Participants With Hereditary Angioedema

🏥 Astria Therapeutics, Inc.📍 79 sites📅 Started Mar 2025View details ↗
Phase 4RecruitingNCT06806657

Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab

👨‍⚕️ Study Director, CSL Behring📍 10 sites📅 Started Mar 2025View details ↗
Phase 1RecruitingNCT07046806

Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients

👨‍⚕️ Henry Li, MD📍 1 site📅 Started Mar 2025View details ↗
NARecruitingNCT06806618

HAE Burden and Crisis Management

👨‍⚕️ Laurence Bouillet, Professor📍 1 site📅 Started Mar 2025View details ↗
Phase 3RecruitingNCT06679881

Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

👨‍⚕️ Study Director, Pharvaris, Pharvaris Netherlands B.V.📍 24 sites📅 Started Feb 2025View details ↗
Phase 3RecruitingNCT06361537

Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks

🏥 Octapharma📍 22 sites📅 Started Apr 2024View details ↗
Enrolling by InvitationNCT06262399

Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002

🏥 Intellia Therapeutics📍 7 sites📅 Started Apr 2024View details ↗
Phase 2, PHASE3Enrolling by InvitationNCT05396105

Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

👨‍⚕️ Study Director, Pharvaris Netherlands B.V.📍 63 sites📅 Started Dec 2022View details ↗
Phase 3Enrolling by InvitationNCT04933721

Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies

👨‍⚕️ Vesna Grivcheva-Panoska, MD, PhD, PHI University Clinic of Dermatology📍 16 sites📅 Started Jul 2021View details ↗
NARecruitingNCT04334031

Deployment o the Multidisciplinary Prospective Cohort Imminent

👨‍⚕️ David Launay, MD,PhD, University Hospital, Lille📍 1 site📅 Started Jul 2020View details ↗

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →